A new American novel draws powerful parallels with Pamuk's Snow LOS ANGELES, September 11, 2010 - In a forthcoming novel of ideas mirroring the breakneck paradigm shifts of the 21st century, Los Angeles writer Armen Melikian engages in a direct conversation with Turkish author Orhan Pamuk's Snow. Melikian's novel, titled Journey to Virginland, tackles a broad array of philosophical, religious, political, sexual, and gender issues discussed by Pamuk, and in a sense continues Snow's narrative on the other side of the border from Kars. Melikian's antihero, a modern day Diogenes called Dog, substantially widens the scope of the investigation which Pamuk's protagonist, Ka, has undertaken to expose a reactionary cultural milieu that has spawned an epidemic of suicides by young women.

Fast Track status is granted to facilitate development and expedite the review of a drug for a serious or potentially fatal illness and to meet an unmet medical need.

LONDON, September 10, 2010 - A global survey conducted by Brand Licensing Europe 2010, Europe's premier licensing trade exhibition, has revealed Manchester United are dominating the fierce battle for licensing revenue across sports teams in Europe. Major retailers such as Debenhams, John Lewis and M&S are still the number one route to market for sport properties.

PERRYSBURG, Ohio and SCHIEDAM, Netherlands, September 10, 2010 - OI European Group B.V., an indirect wholly owned subsidiary of Owens-Illinois Group, Inc., today announced the pricing of its offering of euro 500 million aggregate principal amount of 6.75% Senior Notes due 2020 (the "Notes").

CHICAGO, September 10, 2010 - Celsis In Vitro, Inc. (Celsis IVT) announced today that the United States District Court for the Northern District of Illinois in Chicago has entered a preliminary injunction against CellzDirect Inc., Invitrogen Corporation, and Life Technologies (the Defendants) due to their infringement of U.S. Patent No. 7,604,929 (the Liverpool(TM) patent). Life Technologies of Carlsbad, California (Nasdaq: LIFE) is the parent of Invitrogen and CellzDirect. The Liverpool patent relates to methods for producing multi-cryopreserved hepatocytes and methods for using multi-cryopreserved hepatocytes to investigate in vitro drug metabolism.